| Company/Division name | Diabetes Finished Products |
| Parent company | Novo Nordisk |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Total number of jobs (added or to be added): | 24 |
| Year reshoring announced: | 2018 |
| Capital investment ($): | 65 |
| Country(ies) from which reshored: | Denmark |
| City reshored to: | Clayton |
| State(s) reshored to: | NC |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | diabetes products |
| What domestic positive factors made reshoring more attractive? | Eco-system synergies, Government Incentives, Impact on domestic economy, Skilled workforce availability/training |
